ABIO Share Price

Open 2.45 Change Price %
High 2.45 1 Day -0.05 -2.08
Low 2.35 1 Week -0.05 -2.08
Close 2.35 1 Month -0.20 -7.84
Volume 6827 1 Year -1.05 -30.88
52 Week High 3.93
52 Week Low 2.15
ABIO Important Levels
Resistance 2 2.44
Resistance 1 2.40
Pivot 2.38
Support 1 2.30
Support 2 2.26
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
ASTI 0.00 0.00%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
DCTH 0.02 -33.33%
More..
NASDAQ USA Top Gainers Stocks
HMNY 3.81 55.51%
LOCM 0.09 50.00%
GSOL 17.88 49.00%
OPXAW 0.04 33.33%
WRES 0.09 28.57%
CGEI 0.28 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
BEBE 4.67 23.22%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
HAUP 0.07 -58.82%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

ARCA biopharma, Inc. (NASDAQ: ABIO)

ABIO Technical Analysis 4
As on 23rd May 2017 ABIO Share Price closed @ 2.35 and we RECOMMEND Sell for LONG-TERM with Stoploss of 2.65 & Strong Sell for SHORT-TERM with Stoploss of 2.47 we also expect STOCK to react on Following IMPORTANT LEVELS.
ABIO Target for May
1st Target up-side 2.9
2nd Target up-side 3.07
3rd Target up-side 3.24
1st Target down-side 2.4
2nd Target down-side 2.23
3rd Target down-side 2.06
ABIO Other Details
Segment EQ
Market Capital 4122726.75
Sector Healthcare
Industry Biotechnology
Offical website http://www.arcabiopharma.com
ABIO Address
ABIO
11080 CirclePoint Road
Suite 140
Westminster, CO 80020
United States
Phone: 720-940-2200
ABIO Latest News
Interactive Technical Analysis Chart ARCA biopharma, Inc. ( ABIO NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on ARCA biopharma, Inc.
ABIO Business Profile
ARCA biopharma, Inc. (ARCA), incorporated in 1992, is a bio-pharmaceutical company. The Company’s principal focus is developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA’s lead product candidate is Gencaro TM (bucindolol hydrochloride), a pharmacologically beta-blocker and mild vasodilator being developed for the treatment of chronic heart failure (HF). ARCA biopharma, Inc. is a Colorado-based biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases.The Company has collaborated with LabCorp to develop the Gencaro Test, a companion test for the genetic markers that may predict clinical response to Gencaro. ARCA’s product candidate is Gencaro (bucindolol hydrochloride), a pharmacologically beta-blocker and mild vasodilator being developed for the treatment of chronic heart failure (HF). Gencaro (bucindolol hydrochloride) is a pharmacologically beta-blocker and mild vasodilator being developed for the treatment of AF. Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2 receptors in the cardiac nervous system. The Company Address is Suite 200, 8001 Arista Place, BROOMFIELD CO 80021.